NeurAxis, Inc. entered into a securities purchase agreement for issuance of 1,260,504 series B convertible preferred stock at price of $2.38 per share for gross proceeds of $3,000,000 on November 9, 2023. The transaction will include participation from new investor Flagstaff International, Inc. The aggregate purchase price is to be paid in 15 monthly installments of $200,000 each, commencing on the later of January 10, 2024 or a date after stockholders approve of an amendment to the company?s certificate of incorporation to authorize the creation of the shares. The series B preferred stock is convertible at any time into shares of common stock of the company without any further consideration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.58 USD | -4.44% |
|
-13.13% | -3.37% |
Jun. 07 | NeurAxis Submits Application to FDA to Expand IB-Stim Label | MT |
May. 22 | Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635 | MT |
![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.37% | 17.95M | |
+75.69% | 12.57B | |
+11.91% | 6.92B | |
-29.01% | 6.8B | |
+9.77% | 5.32B | |
-20.60% | 4.63B | |
+13.02% | 3.94B | |
-29.14% | 2.68B | |
+27.73% | 2.06B | |
-1.86% | 2.01B |
- Stock Market
- Equities
- NRXS Stock
- News NeurAxis, Inc.
- NeurAxis, Inc. announced that it expects to receive $3 million in funding from Flagstaff International, Inc